QUAIL-100 for Acute Leukemia

This trial tests a new treatment called QUAIL-100 for individuals with high-risk acute leukemia or myelodysplastic syndrome. The goal is to assess the safety and effectiveness of QUAIL-100 in patients who have already undergone a hematopoietic stem cell transplant, a procedure that replaces damaged blood-forming cells. Participants should have received a specific type of transplant, recovered well, but still face high risks from their disease. The treatment involves a single dose of QUAIL-100. This trial is for those who can confirm they have had the specific transplant and meet the necessary health criteria. As a Phase 1 trial, the research focuses on understanding how QUAIL-100 works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot have planned anti-leukemic therapy within 21 days of dosing or use certain inhibitors within 60 days of screening.

Research shows that QUAIL-100 is currently undergoing safety testing. In the early stages, the main goal is to assess how well people tolerate the treatment. These tests aim to identify any side effects when people take the drug.

As this is the first phase of testing, the focus is on evaluating safety and any unwanted effects. Researchers are still learning about how the drug works in people. Although data is limited, this phase is crucial to ensure the treatment's safety before advancing to further tests.

Most treatments for acute leukemia, such as chemotherapy and targeted therapies, work by attacking rapidly dividing cancer cells. However, QUAIL-100 is unique because it uses a new approach by leveraging live bacteria to potentially target and kill leukemia cells. This novel mechanism of action represents a significant shift from traditional methods, which often have harsh side effects. Researchers are excited about QUAIL-100 because it offers the potential for a more targeted treatment with possibly fewer side effects, providing a new hope for patients with acute leukemia.

Research has shown that QUAIL-100 is being developed to treat high-risk acute leukemia and myelodysplastic syndrome. This trial will assess the effectiveness of QUAIL-100, administered as a single ascending dose, following a hematopoietic stem cell transplant, a procedure that replaces damaged or diseased bone marrow. Although direct data on QUAIL-100's effectiveness in humans is limited, it is designed to specifically target leukemia cells, which is expected to improve outcomes. It may enhance the body's ability to fight cancer cells. Early studies of similar treatments have shown promise in improving survival rates and quality of life for leukemia patients.²³⁶⁷⁸